Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

by Karantza, Vassiliki , Pusztai, Lajos , Denkert, Carsten , Kümmel, Sherko , Park, Yeon Hee , Aktan, Gursel , Hui, Rina , Zhou, Xuan , Tryfonidis, Konstantinos , Schmid, Peter , Cardoso, Fatima , Takahashi, Masato , Fasching, Peter A. , Harbeck, Nadia , Ferreira, Marta , Dent, Rebecca , Foukakis, Theodoros , McArthur, Heather , Cortes, Javier , O’Shaughnessy, Joyce , Untch, Michael , Im, Seock-Ah , Mouret-Reynier, Marie-Ange

in Aged / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Antineoplastic Agents, Immunological - administration & dosage / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Breast Cancer / Cancer therapies / Carboplatin / Carboplatin - administration & dosage / Carboplatin - adverse effects / Chemotherapy / Chemotherapy, Adjuvant - adverse effects / Chemotherapy, Adjuvant - methods / Committees / Cyclophosphamide / Cyclophosphamide - administration & dosage / Cyclophosphamide - adverse effects / Data analysis / Double-Blind Method / Doxorubicin / Epirubicin / Epirubicin - administration & dosage / Epirubicin - adverse effects / Female / Hematology / Humans / Immunotherapy / Kaplan-Meier Estimate / Middle Aged / Monoclonal antibodies / Neoadjuvant Therapy - adverse effects / Neoadjuvant Therapy - methods / Neoplasm Staging / Oncology / Paclitaxel / Paclitaxel - administration & dosage / Paclitaxel - adverse effects / Patients / Pembrolizumab / Placebos / Statistical analysis / Surgery / Survival / Survival Analysis / Targeted cancer therapy / Treatment Outcome / Treatments in Oncology / Triple Negative Breast Neoplasms - drug therapy / Triple Negative Breast Neoplasms - mortality / Triple Negative Breast Neoplasms - pathology / Triple Negative Breast Neoplasms - surgery

2024

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

2024

Confirm

Do you wish to request the book?

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

2024

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Karantza, Vassiliki,

Pusztai, Lajos,

Denkert, Carsten,

Kümmel, Sherko,

Park, Yeon Hee,

Aktan, Gursel,

Hui, Rina,

Zhou, Xuan,

Tryfonidis, Konstantinos,

Schmid, Peter,

Cardoso, Fatima,

Takahashi, Masato,

Fasching, Peter A.,

Harbeck, Nadia,

Ferreira, Marta,

Dent, Rebecca,

Foukakis, Theodoros,

McArthur, Heather,

Cortes, Javier,

O’Shaughnessy, Joyce,

Untch, Michael,

Im, Seock-Ah,

Mouret-Reynier, Marie-Ange

2024

Overview

Among patients with triple-negative breast cancer, 5-year survival was 86.6% with neoadjuvant pembrolizumab with chemotherapy followed by adjuvant pembrolizumab and 81.7% with neoadjuvant chemotherapy alone.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Aged

/ Antibodies, Monoclonal, Humanized - administration & dosage

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antineoplastic Agents, Immunological - administration & dosage

/ Antineoplastic Agents, Immunological - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - administration & dosage

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects